NEW DATA FOR PAZOPANIB - GSK’S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS
Two Phase II studies demonstrated potential for pazopanib as a single agent treatment for early stage non-small cell lung cancer and advanced renal cell cancer
This entry was posted on Sunday, June 1st, 2008 at 9:52 pm and is filed under Research, Non-Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.